Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron

American Journal of Physiology - Renal Physiology

Volumn 310, Issue 11, 2016, Pages F1269-F1283

  Layton, Anita T ^a   Vallon, Volker ^b,c   Edwards, Aurélie ^d  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Diabetes; Glucose; Metabolism; Sodium transport

Indexed keywords

GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOWMAN CAPSULE; CONTROLLED STUDY; DIABETES MELLITUS; GLOMERULUS FILTRATION RATE; GLUCOSE TRANSPORT; GLUCOSURIA; KIDNEY MEDULLA; KIDNEY PROXIMAL TUBULE; NEPHRON; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SODIUM TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DIABETIC NEPHROPATHY; METABOLISM; PHYSIOLOGY;

ANIMALS; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; MODELS, BIOLOGICAL; NEPHRONS; OXYGEN CONSUMPTION; RATS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84984630329     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00543.2015     Document Type: Article

References (61)

1. Bagnasco S, Good D, Balaban R, Burg M. Lactate production in isolated segments of the rat nephron. Am J Physiol Renal Fluid Electrolyte Physiol 248: F522–F526, 1985.
2. 2 consumption, NOS, and Na/H exchange in diabetic rat proximal tubules. Am J Physiol Renal Physiol 283: F286–F293, 2002.
3. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC, EMPA-REG RENAL Trial Investigators. Efficacy and safety of empagliozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, doubleblind, placebo-controlled trial. Lancet Diabetes Endocrinol 2: 369–384, 2014.
4. Bennett KM, Bertram JF, Beeman SC, Gretz N. The emerging role of MRI in quantitative renal glomerular morphology. Am J Physiol Renal Physiol 304: F1252–F1257, 2013.
5. Blount MA, Sands JM, Kent KJ, Smith TK, Price R, Klein JD. Candesartan augments compensatory changes in medullary transport proteins in the diabetic rat kidney. Am J Physiol Renal Physiol 294: F1448– F1452, 2008.
6. Brezis M, Rosen S. Hypoxia of the renal medulla–its implications for disease. N Engl J Med 332: 647–655, 1995.
7. Capasso G, Evangelista C, Zacchia M, Trepiccione F, Acone D, Cantone A, Pollastro RM, Rizzo M. Acid-base transport in Henle’s loop: the effects of reduced renal mass and diabetes. J Nephrol 19, Suppl 9: S11–S17, 2006.
8. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587–597, 2014.
9. Dickman KG, Mandel LJ. Differential effects of respiratory inhibitors on glycolysis in proximal tubules. Am J Physiol Renal Fluid Electrolyte Physiol 258: F1608–F1615, 1990.
10. Du Z, Yan Q, Duan Y, Weinbaum S, Weinstein AM, Wang T. Axial flow modulates proximal tubule NHE3 and H-ATPase activities by changing microvillous bending moments. Am J Physiol Renal Physiol 290: F289–F296, 2006.
11. Edwards A. Regulation of calcium reabsorption along the rat nephron: a modeling study. Am J Physiol Renal Physiol 308: F553–F566, 2015.
12. Edwards A, Castrop H, Laghmani K, Vallon V, Layton AT. Effects of NKCC2 isoform regulation on NaCl transport in thick ascending limb and macula densa: a modeling study. Am J Physiol Renal Physiol 307: F137–F146, 2014.
13. +/glucose cotransporter. J Membr Biol 204: 23–32, 2005.
14. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl 75: S22–S26, 2000.
15. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 74: 867–872, 2008.
16. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Rrenal Data System. J Am Soc Nephrol 18: 2644–2648, 2007.
17. Franzen S, Palm F. Endothelin type A receptor inhibition normalises intrarenal hypoxia in rats used as a model of type 1 diabetes by improving oxygen delivery. Diabetologia 58: 2435–2442, 2015.
18. Friederich-Persson M, Thorn E, Hansell P, Nangaku M, Levin M, Palm F. Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension 62: 914–919, 2013.
19. Holtkamp FA, Zeeuw de D, Thomas MC, Cooper ME, Graeff de PA, Hillege HJL, Parving HH, Brenner BM, Shahinfar S, Heerspink HJ. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80: 282–287, 2011.
20. Jauch P, Lauger P. Electrogenic properties of the sodium-alanine cotransporter in pancreatic acinar cells: II. Comparison with transport models. J Memb Biol 94: 117–127, 1986.
21. Khadouri C, Barlet-Bas C, Doucet A. Mechanism of increased tubular Na-K-ATPase during streptozotocin-induced diabetes. Pflügers Arch 409: 296–301, 1987.
22. Kim D, Sands JM, Klein JD. Role of vasopressin in diabetes mellitusinduced changes in medullary transport proteins involved in urine concentration in Brattleboro rats. Am J Physiol Renal Physiol 286: F760– F766, 2004.
23. Klahr S, Hamm LL, Hammerman MR, Mandel LJ. Renal metabolism: integrated responses. The Gastrointestinal System. In: Handbook of Physiology, edited by Orloff J, Berliner RW. Bethesda, MD: Am. Physiol. Soc., sect. 8, 1989.
24. Klein JD, Rash A, Sands JM, Ecelbarger CM, Tiwari S. Candesartan differentially regulates epithelial sodium channel in cortex versus medulla of streptozotocin-induced diabetic rats. J Epithel Biol Pharmacol 2: 23, 2009.
25. Körner A, Eklöf AC, Celsi G, Aperia A. Increased renal metabolism in diabetes: mechanism and functional implications. Diabetes 43: 629–633, 1994.
26. Layton AT, Vallon V, Edwards A. Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. Am J Physiol Renal Physiol 308: F1343–F1357, 2015.
27. Maki LW, Keizer J. Mathematical analysis of a proposed mechanism for oscillatory insulin secretion in perfused HIT-15 cells. Bull Math Biol 57: 569–591, 1995.
28. Nejsum LN, Kwon TW, Marples D, Flyvbjerg A, Knepper MA, Froklaer J, Nielsen S. Compensatory increase in AQP2, p-AQP2, and AQP3 expression in rats with diabetes mellitus. Am J Physiol Renal Physiol 280: F715–F726, 2001.
29. Neuhofer W, Beck FX. Cell survival in the hostile environment of the renal medulla. Annu Rev Physiol 67: 531–555, 2005.
30. Nordquist L, Friederich-Persson M, Fasching A, Liss P, Shoji K, Nangaku M, Hansell P, Palm F. Activation of hypoxia-inducible factors prevents diabetic nephropathy. J Am Soc Nephrol 26: 328–338, 2015.
31. 1-subunit in rats. Diabetes Metab Res Rev 26: 193– 199, 2010.
32. 2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol Renal Physiol 277: F404–F412, 1999.
33. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose cotransport 2 (SGLT2) inhibitors. J Am Soc Hypertens 8: 330–339, 2014.
34. O’Neill J, Fasching A, Pihl L, Patinha D, Franzén S, Palm F. Acute SGLT inhibition normalizes oxygen tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 309: F227–F234, 2015.
35. Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia 46: 1153–1160, 2003.
36. Palm F, Hansell P, Ronquist G, Waldenstrom A, Liss P, Carlsson PO. Polyol-pathway-dependent disturbances in renal medullary metabolism in experimental insulin- deficient diabetes mellitus in rats. Diabetologia 47: 1223–1231, 2004.
37. +/glucose cotransporter: II. A transport model under nonrapid equilibrium conditions. J Membr Biol 125: 63–79, 1992.
38. Pennell JP, Lacy FB, Jamison RL. An in vivo study of the concentrating process in the descending limb of Henle’s loop. Kidney Int 5: 337–347, 1974.
39. Riazi S, Maric C, Ecelbarger CA. 17-βEstradiol attenuates streptozotocin-induced diabetes and regulates the expression of renal sodium transporters. Kidney Int 69: 471480, 2006.
40. Rich PR. The molecular machinery of Keilin’s respiratory chain. Biochem Soc Trans 6: 1095–1105, 2003.
41. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, Vallon V. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306: F188–F193, 2014.
42. 1-subunits in diabetic rat kidneys using RT-PCR. Am J Physiol Renal Physiol 282: F492–F500, 2002.
43. Song J, Knepper MA, Verbalis JG, Ecelbarger CA. Increased renal ENaC subunit and sodium transporter abundances in streptozotocin-induced type 1 diabetes. Am J Physiol Renal Physiol 285: F1125–F1137, 2003.
44. Stokes JB, Grupp SC, Kinne RK. Purification of rat papillary collecting duct cells: functional and metabolic assessment. Am J Physiol Renal Fluid Electrolyte Physiol 253: F251–F262, 1987.
45. Tanaka S, Tanaka T, Nnagaku M. Hypoxia as a key player in the AKI-to-CKD transition. Am J Physiol Renal Physiol 307: F1187–F1195, 2014.
46. Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302: R75–R83, 2012.
47. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66: 255–270, 2015.
48. Vallon V, Gerasimova MM, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T. SGLT2 inhibitor empagliozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306: F194–F204, 2014.
49. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus potential role of tubular reabsorption. J Am Soc Nephrol 10: 2569–2576, 1999.
50. Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, Sharma K, Thomson SC, Rieg T. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304: F156–F167, 2013.
51. Vidotti DB, Arnoni CP, Maquigussa E, Boim MA. Effect of long-term type 1 diabetes on renal sodium and water transporters in rats. Am J Nephrol 28: 107–114, 2008.
52. Wade JB, Lee AJ, Ecelbarger CA, Mitchell C, Bradford AD, Terris J, Kim GH, Knepper MA. UT-A2: a 55-kDa urea transporter in thin descending limb whose abundance is regulated by vasopressin. Am J Physiol Renal Physiol 278: F52–F62, 2000.
53. Weinstein AM. A mathematical model of rat collecting duct. I. Flow effects on transport and urinary acidification. Am J Physiol Renal Physiol 283: F1237–F1251, 2002.
54. Weinstein AM. Potassium excretion during antinatriuresis: perspective from a distal nephron model. Am J Physiol Renal Physiol 302: F658– F673, 2012.
55. Weinstein AM. A mathematical model of the rat nephron: glucose transport. Am J Physiol Renal Physiol 308: F1098–F1118, 2015.
56. Weinstein AM, Weinbaum S, Duan Y, Du ZP, Yan QS, andWang TG. Flow-dependent transport in a mathematical model of rat proximal tubule. Am J Physiol Renal Physiol 292: F1164–F1181, 2007.
57. O2 and renal oxygen usage in the hypertensive rate kidney. Kidney Int 59: 230–237, 2001.
58. Yal e JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G. Efficacy and safety of canagliozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15: 463–473, 2013.
59. Yamout H, Lazich I, Bakris GL. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv Chronic Kidney Dis 21: 281–4286, 2014.
60. Yang J, Pollock JS, Carmines PK. NADPH oxidase and PKC contribute to increased Na transport by the thick ascending limb during type 1 diabetes. Hypertension 59: 431–436, 2012.
61. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheusa M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Empagliozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128, 2015.